JP2006511211A5 - - Google Patents

Download PDF

Info

Publication number
JP2006511211A5
JP2006511211A5 JP2004538747A JP2004538747A JP2006511211A5 JP 2006511211 A5 JP2006511211 A5 JP 2006511211A5 JP 2004538747 A JP2004538747 A JP 2004538747A JP 2004538747 A JP2004538747 A JP 2004538747A JP 2006511211 A5 JP2006511211 A5 JP 2006511211A5
Authority
JP
Japan
Prior art keywords
expression construct
seq
dna expression
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004538747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006511211A (ja
JP4411213B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DE2003/003179 external-priority patent/WO2004028562A2/de
Publication of JP2006511211A publication Critical patent/JP2006511211A/ja
Publication of JP2006511211A5 publication Critical patent/JP2006511211A5/ja
Application granted granted Critical
Publication of JP4411213B2 publication Critical patent/JP4411213B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004538747A 2002-09-23 2003-09-19 ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン Expired - Fee Related JP4411213B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10244863 2002-09-23
PCT/DE2003/003179 WO2004028562A2 (de) 2002-09-23 2003-09-19 Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze

Publications (3)

Publication Number Publication Date
JP2006511211A JP2006511211A (ja) 2006-04-06
JP2006511211A5 true JP2006511211A5 (enExample) 2006-11-09
JP4411213B2 JP4411213B2 (ja) 2010-02-10

Family

ID=32038184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004538747A Expired - Fee Related JP4411213B2 (ja) 2002-09-23 2003-09-19 ネコ白血病ウィルスによるネコ感染症のようなオンコウィルス感染症に対するワクチン

Country Status (9)

Country Link
US (1) US7915035B2 (enExample)
EP (1) EP1553977B1 (enExample)
JP (1) JP4411213B2 (enExample)
AT (1) ATE335507T1 (enExample)
AU (1) AU2003281917A1 (enExample)
DE (2) DE50304603D1 (enExample)
DK (1) DK1553977T3 (enExample)
ES (1) ES2270120T3 (enExample)
WO (1) WO2004028562A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0901593D0 (en) * 2009-01-30 2009-03-11 Touchlight Genetics Ltd Production of closed linear DNA
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
GB201013153D0 (en) 2010-08-04 2010-09-22 Touchlight Genetics Ltd Primer for production of closed linear DNA
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
EP3706789A1 (en) 2017-11-06 2020-09-16 Intervet International B.V. Feline calicivirus vaccine
CA3080427A1 (en) * 2017-11-06 2019-05-09 Intervet International B.V. Feline leukemia virus vaccine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU607399B2 (en) * 1985-09-09 1991-03-07 Cetus Corporation Infectious recombinant virus vaccine for feline leukemia
AU672359B2 (en) * 1991-03-07 1996-10-03 Virogenetics Corporation Genetically engineered vaccine strain
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
DE19648625A1 (de) * 1996-11-13 1998-05-14 Soft Gene Gmbh Mikroprojektil für das Einbringen von Substanzen in Zellen durch ballistischen Transfer
US6696291B2 (en) * 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
US6248582B1 (en) * 1997-10-08 2001-06-19 Imran Khan Gene deleted recombinant FeLV proviral DNA for production of vaccines against FeLV
SE9803099D0 (sv) * 1998-09-13 1998-09-13 Karolinska Innovations Ab Nucleic acid transfer
WO2003031470A2 (de) * 2001-10-02 2003-04-17 Mologen Ag Dna-expressionskonstrukt zur behandlung von infektionen mit leishmaniose

Similar Documents

Publication Publication Date Title
US20190315642A1 (en) Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome
JP3830525B2 (ja) 組織横断輸送を強化するペプチドとその同定法および使用法
JPWO2022067130A5 (enExample)
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
US9676641B2 (en) Therapeutic phages and methods for delivery of nucleic acids for therapeutic uses
JP2012532601A5 (enExample)
JP2008529558A5 (enExample)
JP2004503213A5 (enExample)
JP2020510426A5 (enExample)
JP2010512160A5 (enExample)
JP2007516696A5 (enExample)
AU2025205053A1 (en) Compositions including Sbi adjuvants and methods of use thereof
JP2006511211A5 (enExample)
CN116782928A (zh) 能够将抗原递送至mhc-ii途径并在宿主中诱导cd4+和cd8+t细胞应答的慢病毒载体
FR2726576A1 (fr) Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
JP2002536418A5 (enExample)
CN116209771A (zh) 用于改善疫苗接种的组合物和方法
CN104404069B (zh) 一种低拷贝pTerm质粒及其构建方法和应用
JP2008521384A (ja) コロナウィルス様粒子をコードする発現ベクター
WO2002068662A8 (en) Plasmid originated from bifidobacterium, recombinant expression vector using the plasmid and transformation method
JP2003334089A5 (enExample)
CN112725378A (zh) 一种人工改造的akt3环状rna及其在新冠疫苗中的应用
JP2005526511A5 (enExample)
ATE458037T1 (de) Grosstechnisch geeigneter mikroorganismus
FI117897B (fi) Punkin kantaman aivotulehdus- (TBE) viruksen tarttuva cDNA-klooni, siitä saatu yhdistelmä-DNA-rokote ja tämän valmistus